Healthy Inc > Blog > Sulfonylurea manufacturer India
Posted on:

What is gliclazide 80 mg used for?

In the pharmaceutical industry, Gliclazide 80 mg is a second-generation sulfonylurea antidiabetic agent. As a pharmacist, I characterize Gliclazide as a “preferred” sulfonylurea because it offers a lower risk of hypoglycemia and weight gain compared to older agents like Glibenclamide, making it a staple in long-term metabolic management.

Primary Clinical Use

  • Type 2 Diabetes Mellitus (T2DM): It is indicated for the control of blood glucose in adults when dietary modifications, physical exercise, and weight reduction alone are not sufficient. It is often used as a second-line therapy after Metformin or as a component of dual/triple therapy.

Mechanism of Action

Gliclazide is an insulin secretagogue. It acts primarily by stimulating the beta cells of the pancreas to release more insulin.

Binding to SUR1: It binds to specific sulfonylurea receptors (SUR1) on the surface of pancreatic beta cells.

ATP-sensitive Potassium Channel Closure: This binding causes the closure of potassium channels, leading to cell depolarization.

Insulin Secretion: Depolarization opens voltage-gated calcium channels; the resulting influx of calcium triggers the exocytosis (release) of insulin into the bloodstream.

Extrapancreatic Effects: It also improves peripheral insulin sensitivity and reduces glucose output from the liver.

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, Gliclazide 80 mg is a high-demand, high-precision product:

  • Immediate Release (IR) vs. Sustained Release (SR): The 80 mg strength is typically the Immediate Release format. As a WHO-GMP manufacturer, we ensure the disintegration time is tightly controlled to provide a rapid post-prandial (after-meal) insulin spike.

  • Hemovascular Properties: Unique to Gliclazide is its ability to reduce microthrombosis (small blood clots) by inhibiting platelet aggregation. As a firm owner, you can market this “extra” benefit to B2B buyers focused on preventing diabetic complications like retinopathy.

  • Stability for Global Trade: Gliclazide is stable, but we utilize Alu-Alu or high-grade PVC/PVDC blister packaging to ensure a 36-month shelf life for export to Zone IVb climates (Africa, SE Asia, and the Middle East).

  • Dossier & Registration: Our Mumbai-based facility provides full CTD/eCTD Dossiers and comparative dissolution data against the innovator (Diamicron) to facilitate registration for our international B2B partners.

Gliclazide Tablets

Posted on:

Is glibenclamide safe for kidneys?

To give you a straight, technical answer as a partner in the pharmaceutical trade: Glibenclamide is generally not considered the safest choice for patients with significant kidney impairment.

In the industry, we often classify Glibenclamide (a second-generation sulfonylurea) as a “high-risk” medication for renal patients due to its specific metabolic pathway and the danger of prolonged hypoglycemia.

Technical Analysis: Why it is a Concern for Kidneys

1. Active Metabolites and Bioaccumulation

Unlike some other sulfonylureas, Glibenclamide is metabolized in the liver into active metabolites.

  • The Renal Connection: These metabolites are primarily excreted through the kidneys (roughly 50%).

  • The Risk: In patients with Chronic Kidney Disease (CKD) or impaired renal function, these active metabolites cannot be cleared efficiently. They accumulate in the bloodstream, continuing to stimulate the pancreas to release insulin long after they should have been cleared.

2. Severe and Prolonged Hypoglycemia

The primary safety concern isn’t that the drug “damages” the kidneys further (it is not inherently nephrotoxic), but rather that the kidneys cannot get rid of it. This leads to prolonged hypoglycemia, which can be life-threatening and much harder to treat than standard low blood sugar because the drug stays in the system for an extended period.

3. Clinical Guidelines (e.g., KDIGO/ADA)

  • Mild Impairment: May be used with extreme caution and low dosing.

  • Moderate to Severe Impairment (eGFR < 60 mL/min): Generally contraindicated or strictly discouraged.

  • Preferred Alternatives: In your B2B trading or manufacturing portfolio, you’ll find that Gliclazide or Glipizide are preferred because they have inactive metabolites, or Linagliptin (an Gliptin) is favored as it has non-renal excretion.

The Manufacturer’s Perspective: Positioning for Export

As you develop your digital platforms and multivendor marketplace, how you position Glibenclamide is crucial for regulatory compliance:

  • Warning Labels: Your Product Information Leaflets (PIL) must include a clear contraindication for patients with severe renal impairment (Stage 4 or 5 CKD).

  • B2B Strategy: When dealing with international tenders (especially for older populations), highlighting that your firm also carries “Renal-Safe” options like Gliclazide or Sitagliptin adds significant value to your “Technical Partner” status.

  • Quality Control: As a WHO-GMP firm, ensuring high-quality dissolution profiles is vital, as any “dose dumping” in a renal patient could be catastrophic.

Glibenclamide Tablets

 

Add to cart